Table 2.
Plasma cytokines portraits of primary ITP patients (pg/ml)
| Health control (n = 10) | Primary ITP (n = 23) | |
|---|---|---|
| Eotaxin-1/CCL11 | 220.40 (195.40–220.40) | 154.5 (106.80–189.10)*** |
| Eotaxin-2 (×103) | 1.17 (0.84–2.20) | 0.92 (0.49–1.41) |
| G-CSF | 825.40 (562.20–855.90) | 76.70 (37.00–175.90)*** |
| GM-CSF | 80.05 (66.35–97.28) | 11.00 (8.00–16.90)*** |
| I-309 | 83.70 (68.45–134.50) | 33.70 (19.60–55.70)*** |
| ICAM-1 (×103) | 39.40 (16.75–43.33) | 21.87 (6.46–45.08) |
| IFNγ (×103) | 0.79 (0.71–0.94) | 0.16 (0.12–0.20)** |
| IL-1α (×103) | 1.16 (0.94–1.33) | 0.20 (0.11–0.45)*** |
| IL-1β | 65.75 (59.90–79.70) | 37.80 (24.10–47.50)*** |
| IL-1ra (×103) | 1.28 (1.01–1.63) | 0.35 (0.26–0.41)*** |
| IL-2 | 264.90 (187.80–343.20) | 44.90 (33.10–71.60)*** |
| IL-4 | 415.40 (340.80–504.10) | 110.5 (54.7–164.0)*** |
| IL-5 | 185.40 (158.00–243.40) | 42.10 (32.70–51.60)*** |
| IL-6 | 83.90 (59.03–101.40) | 16.50 (7.90–26.80)*** |
| IL-6R (×103) | 17.90 (17.86–18.78) | 17.80 (17.80–18.90) |
| IL-7 | 130.30 (96.93–147.60) | 26.20 (22.10–34.60)*** |
| IL-8 | 99.40 (75.40–121.80) | 11.90 (7.70–19.30)*** |
| IL-10 | 94.45 (63.40–192.20) | 17.10 (11.10–23.40)*** |
| IL-11 (×103) | 1.43 (1.07–1.93) | 0.41 (0.24–0.53)*** |
| IL-12p40 | 15.85 (12.20–26.78) | 13.50 (4.50–18.10) |
| IL-12p70 | 41.85 (28.08–55.05) | 7.30 (4.60–9.80)*** |
| IL-13 | 37.80 (26.48–46.33) | 10.10 (6.10–12.90)*** |
| IL-15 | 57.50 (35.35–71.68) | 27.60 (12.20–36.90)* |
| IL-16 | 124.40 (75.65–171.50) | 62.30 (31.80–106.60)* |
| IL-17A | 29.95 (14.50–41.38) | 4.00 (1.80–6.80)*** |
| MCP-1 (×103) | 0.30 (0.27–0.35) | 0.16 (0.12–0.30)** |
| M-CSF | 20.45 (16.28–28.30) | 8.20 (4.20–14.00)** |
| CXCL9/MIG | 52.55 (39.88–67.83) | 44.60 (25.80–55.00) |
| MIP-1α/CCL3 | 25.10 (20.45–30.30) | 17.30 (10.60–24.30)* |
| MIP-1β | 97.05 (88.08–140.40) | 85.50 (63.50–155.00) |
| MIP-1d (×103) | 1.31 (0.88–2.95) | 1.80 (0.95–2.94) |
| PDGF-BB (×103) | 5.36 (3.87–6.72) | 0.70 (0.34–1.82)*** |
| RANTES (×103) | 14.62 (13.92–15.71) | 8.90 (4.08–14.59)** |
| TIMP-1 (×103) | 8.21 (7.00–10.29) | 16.13 (11.99–19.03)*** |
| TIMP-2 (×103) | 20.46 (13.93–32.76) | 11.92 (7.81–14.82)** |
| TNFα (×103) | 1.06 (0.71–1.80) | 0.24 (0.15–0.37)*** |
| TNFβ (×103) | 0.90 (0.70–1.65) | 0.30 (0.21–0.38)*** |
| TNFRI (×103) | 5.21 (4.11–5.93) | 7.02 (5.40–13.51)* |
| TNFRII (×104) | 1.80 (1.53–2.01) | 2.12 (1.82–3.17)* |
Data are presented as median (interquartile range)
CCL11 CeC motif chemokine 11, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte–macrophage colony-stimulating factor, ICAM-1 intercellular adhesion molecule-1, IFNγ interferon-gamma, IL interleukin, MCP-1 monocyte chemoattractant protein-1, M-CSF macrophage colony-stimulating factor, CXCL9 CXC ligand 9, MIP macrophage-inflammatory protein, PDGF-BB platelet-derived growth factor BB, RANTES regulated on activation normal T expressed and secreted chemokines, TIMP tissue inhibitor of metalloproteinases, TNF tumor necrosis factor, TNFR tumor necrosis factor receptor
* p < 0.05; ** p < 0.01; *** p < 0.001, ITP(n = 23) compared with HC(n = 10)